DB18742InvestigationalSmall molecule
SPG601 is being investigated for the treatment of fragile X syndrome.
- Mechanism
- Curator reviewed
Pharmacologically active on Calcium-activated potassium channel subunit alpha-1
- Also known as
- (R) 3-(5-Dimethylcarbamoyl-pent-1-enyl)-N-(2-hydroxy-1-methylethyl) benzamide
- Code names
- SPG-601
Resolves to
Targets
What you can answer from here — as of July 09, 2026
Which drugs share a target with SPG601, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account